Key Points
- Major shareholder Chidozie Ugwumba sold 5,869 shares on Jan 5 at an average of $5.87 for $34,451, and after the transaction he directly owns 760,611 shares (a 0.77% reduction, ~ $4.46M value).
- Ugwumba has executed a string of insider sales from Dec 22 through Jan 7 (multiple tranches including Dec 22, Dec 29–31, Jan 2, Jan 5–7), indicating a sustained selling pattern over recent weeks.
- Clene shares trade near $6.28 with a market cap of about $64.9M; the company recently missed quarterly EPS estimates and, despite mixed analyst opinions, carries a consensus rating of "Moderate Buy" with a $32.60 target.
Clene Inc. (NASDAQ:CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 3,111 shares of the firm's stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $6.04, for a total value of $18,790.44. Following the sale, the insider directly owned 757,500 shares of the company's stock, valued at $4,575,300. This trade represents a 0.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.
Chidozie Ugwumba also recently made the following trade(s):
- On Wednesday, January 7th, Chidozie Ugwumba sold 3,938 shares of Clene stock. The shares were sold at an average price of $6.29, for a total value of $24,770.02.
- On Monday, January 5th, Chidozie Ugwumba sold 5,869 shares of Clene stock. The stock was sold at an average price of $5.87, for a total transaction of $34,451.03.
- On Friday, January 2nd, Chidozie Ugwumba sold 4,015 shares of Clene stock. The stock was sold at an average price of $5.73, for a total transaction of $23,005.95.
- On Wednesday, December 31st, Chidozie Ugwumba sold 13,095 shares of Clene stock. The shares were sold at an average price of $5.81, for a total transaction of $76,081.95.
- On Tuesday, December 30th, Chidozie Ugwumba sold 4,138 shares of Clene stock. The shares were sold at an average price of $6.03, for a total transaction of $24,952.14.
- On Monday, December 29th, Chidozie Ugwumba sold 8,096 shares of Clene stock. The stock was sold at an average price of $5.95, for a total transaction of $48,171.20.
- On Tuesday, December 23rd, Chidozie Ugwumba sold 6,831 shares of Clene stock. The stock was sold at an average price of $6.27, for a total transaction of $42,830.37.
- On Friday, December 26th, Chidozie Ugwumba sold 3,350 shares of Clene stock. The shares were sold at an average price of $6.32, for a total value of $21,172.00.
- On Wednesday, December 24th, Chidozie Ugwumba sold 1,490 shares of Clene stock. The stock was sold at an average price of $6.27, for a total value of $9,342.30.
- On Monday, December 22nd, Chidozie Ugwumba sold 4,367 shares of Clene stock. The stock was sold at an average price of $6.54, for a total value of $28,560.18.
Clene Stock Performance
Shares of NASDAQ CLNN opened at $6.28 on Thursday. The business's 50-day simple moving average is $7.88 and its 200-day simple moving average is $6.39. Clene Inc. has a 52 week low of $2.28 and a 52 week high of $13.50. The firm has a market cap of $64.87 million, a price-to-earnings ratio of -1.85 and a beta of 0.87.
Clene (NASDAQ:CLNN - Get Free Report) last posted its earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The company had revenue of $0.02 million during the quarter, compared to analysts' expectations of $0.06 million. As a group, equities research analysts forecast that Clene Inc. will post -5.19 earnings per share for the current year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the stock. Jones Financial Companies Lllp bought a new stake in shares of Clene in the third quarter valued at about $29,000. Jane Street Group LLC bought a new position in Clene during the second quarter valued at about $47,000. Lunt Capital Management Inc. raised its holdings in Clene by 71.2% in the 2nd quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company's stock valued at $199,000 after acquiring an additional 21,217 shares in the last quarter. Finally, Scoggin Management LP lifted its position in shares of Clene by 42.8% in the 2nd quarter. Scoggin Management LP now owns 142,750 shares of the company's stock worth $558,000 after acquiring an additional 42,750 shares during the period. Institutional investors and hedge funds own 23.28% of the company's stock.
Wall Street Analyst Weigh In
Several research analysts recently commented on CLNN shares. Benchmark reiterated a "buy" rating on shares of Clene in a report on Thursday, December 4th. UBS Group reaffirmed a "buy" rating on shares of Clene in a research report on Wednesday, December 3rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Clene in a research note on Tuesday, October 14th. Finally, D. Boral Capital restated a "buy" rating and set a $23.00 target price on shares of Clene in a research note on Wednesday, December 10th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $32.60.
Get Our Latest Report on CLNN
Clene Company Profile
(
Get Free Report)
Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company's flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene's platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.
Clene's lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis (MS).
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
